Pediculosis.com is the world's only website aimed specifically at researchers, product managers and buyers in the head lice industry.
We provide regularly-updated information on new products, industry changes, regulatory issues, clinical trials and studies to help you identify emerging global trends and business opportunities.
Hatchtech Pty Ltd this week announced successful results for its phase 3 trials of Xeglyze™ Lotion, a novel lice and egg treatment.
The studies comprised 704 subjects receiving a single ten-minute application of Xeglyze™ Lotion, resulting in 81.5% of subjects remaining lice free through to the 14-day follow-up point. This represents a statistically significant increase in anti-lice treatment versus the control.
There were few adverse effects reported, and none were serious in nature.
The active ingredient of Xeglyze™ Lotion is known to inhibit key pathways in the life cycle of the head louse, including the egg, supported by both published results and patent information.
Hatchtech intend to file a New Drug Application with the US Food and Drug Administration in 2015.